Siemens introduces ACUSON Antares ultasound

Siemens Medical Solutions this week introduced its new ACUSON Antares ultrasound system at the 15th International Society of Ultrasound in Obstetrics & Gynecology (ISUOG) World Congress in Vancouver. The new 'premium edition' Antares system is upgradeable and serves as comprehensive clinical capabilities, research functions, enhanced workflow efficiencies, and user-friendly ergonomics, Siemens said.
        
"The introduction of the ACUSON Antares system, premium edition, creates a common brand for our high-end ultrasound systems, offering an even higher level of diagnostic confidence," said Arnd Kaldowski, vice president, global sales and marketing, Ultrasound Division, Siemens Medical Solutions, in a release. "It presents all the elements of a complete premium-performance solution, from acquisition to archive, from 2D through 4D, providing integrated tools for busy and diverse clinical practices and research institutions."

New features of the ultrasound system include:
  • The fourSight 4D ultrasound imaging technology, which addresses increasing clinical needs for imaging throughout entire pregnancy, including first trimester studies. The new EV9F4 endovaginal transducer has a 173-degree field-of-view that expands the clinical utility of 3D/4D examinations by providing additional diagnostic information to gynecological ultrasound studies not available with standard 2D exams;

  • A full suite of Hanafy Lens and Multi-D array transducers;

  • 2D and Spectral TEQ ultrasound technology that automatically optimizes both 2D and spectral Doppler images with a touch of a single button;

  • Clarify vascular enhancement technology;

  • Cadence contrast pulse sequencing (CPS) technology option, the company's contrast imaging technology which has been migrated from the ACUSON Sequoia ultrasound system.

Around the web

RBMA President Peter Moffatt discusses some of the biggest obstacles facing the specialty in the new year. 

Deepak Bhatt, MD, director of the Mount Sinai Fuster Heart Hospital and principal investigator of the TRANSFORM trial, explains an emerging technique for cardiac screening: combining coronary CT angiography with artificial intelligence for plaque analysis to create an approach similar to mammography.

A total of 16 cardiology practices from 12 states settled with the DOJ to resolve allegations they overbilled Medicare for imaging agents used to diagnose cardiovascular disease.